Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 278.60K | 14.30K | 109.70K | 255.00K | 238.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 278.60K | 14.30K | 109.70K | 255.00K | 238.10K |
| Cost of Revenue | 380.70K | 548.20K | 405.40K | 455.00K | 547.00K |
| Gross Profit | -102.00K | -533.90K | -295.60K | -200.00K | -308.90K |
| SG&A Expenses | 874.90K | 1.74M | 460.30K | 448.90K | -38.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.26M | 2.29M | 865.60K | 903.90K | 508.50K |
| Operating Income | -976.90K | -2.27M | -755.90K | -648.90K | -270.40K |
| Income Before Tax | -1.16M | -2.40M | -1.01M | -846.80K | -504.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.16M | -2.40M | -1.01M | -846.80K | -504.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 21.50K | -- | -- | -- | -- |
| Net Income | -1.14M | -2.40M | -1.01M | -846.80K | -504.00K |
| EBIT | -976.90K | -2.27M | -755.90K | -648.90K | -270.40K |
| EBITDA | -976.50K | -2.27M | -753.70K | -646.70K | -268.20K |
| EPS Basic | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 420.28M | 420.29M | 419.91M | 419.52M | 419.52M |
| Average Diluted Shares Outstanding | 420.28M | 420.29M | 419.91M | 419.52M | 419.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |